(Q37218108)

19 August 2017

1 reference

title

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors (English)

1 reference

19 August 2017

1 reference

Josep M Cruzado

1

1 reference

19 August 2017

1 January 2008

1 reference

19 August 2017

Transplantation Reviews

1 reference

19 August 2017

22

1 reference

19 August 2017

1

1 reference

19 August 2017

73-81

1 reference

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Are we ready to give up on calcineurin inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Calcineurin inhibitor-free immunosuppression in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Mycophenolate mofetil and sirolimus combination in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

TOR, a central controller of cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The making of a queen: TOR pathway is a key player in diphenic caste development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

A link between protein translation and body weight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Overcoming restenosis with sirolimus: from alphabet soup to clinical reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin inhibits vascular smooth muscle cell migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin attenuates load-induced cardiac hypertrophy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The "thrifty genotype" in 1998

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Hypothalamic mTOR signaling regulates food intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

mTOR tells the brain that the body is hungry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Cancer After Renal Transplantation: The Next Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Malignancy after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

The role of proliferation signal inhibitors in post-transplant malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

mRNA translation: unexplored territory in renal science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Influence of nephron mass in development of chronic renal failure after prolonged warm renal ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of Reduced Renal Mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Extracellular matrix metabolism in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Autosomal dominant polycystic kidney disease: time for a change?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

New immunosuppresor strategies in the treatment of murine lupus nephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2007.09.003

10.1016/J.TRRE.2007.09.003

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18631860